Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer

Lung cancer is a malignant tumor with the highest mortality in the world. The most common pathological type of lung cancer is non-small cell lung cancer (NSCLC). In recent years, immunotherapy has brought about epoch-making changes in the treatment of NSCLC. In particular, immune checkpoint inhibito...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chuan HUANG, Xue YANG
Formato:	article
Lenguaje:	ZH
Publicado:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021
Materias:	lung neoplasms immunotherapy biomarker Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ae484970d4ee4d4ab5327fcf84f9f91a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ae484970d4ee4d4ab5327fcf84f9f91a
record_format	dspace
spelling	oai:doaj.org-article:ae484970d4ee4d4ab5327fcf84f9f91a2021-11-19T06:49:15ZAdvances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer1009-34191999-618710.3779/j.issn.1009-3419.2021.102.40https://doaj.org/article/ae484970d4ee4d4ab5327fcf84f9f91a2021-11-01T00:00:00Zhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.40https://doaj.org/toc/1009-3419https://doaj.org/toc/1999-6187Lung cancer is a malignant tumor with the highest mortality in the world. The most common pathological type of lung cancer is non-small cell lung cancer (NSCLC). In recent years, immunotherapy has brought about epoch-making changes in the treatment of NSCLC. In particular, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have been approved for first-line and second-line treatment in patients with metastatic NSCLC. However, only 15% to 30% of patients with advanced NSCLC can achieve sustained remission and long-term survival from immunotherapy. Therefore, biomarker for predicting the efficacy of immunotherapy is particularly important. This article reviews the relevant literatures on predictive biomarkers for immunotherapy of NSCLC and provides direction for future research.Chuan HUANGXue YANGChinese Anti-Cancer Association; Chinese Antituberculosis Associationarticlelung neoplasmsimmunotherapybiomarkerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHChinese Journal of Lung Cancer, Vol 24, Iss 11, Pp 777-783 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	lung neoplasms immunotherapy biomarker Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung neoplasms immunotherapy biomarker Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chuan HUANG Xue YANG Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
description	Lung cancer is a malignant tumor with the highest mortality in the world. The most common pathological type of lung cancer is non-small cell lung cancer (NSCLC). In recent years, immunotherapy has brought about epoch-making changes in the treatment of NSCLC. In particular, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have been approved for first-line and second-line treatment in patients with metastatic NSCLC. However, only 15% to 30% of patients with advanced NSCLC can achieve sustained remission and long-term survival from immunotherapy. Therefore, biomarker for predicting the efficacy of immunotherapy is particularly important. This article reviews the relevant literatures on predictive biomarkers for immunotherapy of NSCLC and provides direction for future research.
format	article
author	Chuan HUANG Xue YANG
author_facet	Chuan HUANG Xue YANG
author_sort	Chuan HUANG
title	Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
title_short	Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
title_full	Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
title_fullStr	Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
title_full_unstemmed	Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
title_sort	advances in biomarkers for immunotherapy of non-small cell lung cancer
publisher	Chinese Anti-Cancer Association; Chinese Antituberculosis Association
publishDate	2021
url	https://doaj.org/article/ae484970d4ee4d4ab5327fcf84f9f91a
work_keys_str_mv	AT chuanhuang advancesinbiomarkersforimmunotherapyofnonsmallcelllungcancer AT xueyang advancesinbiomarkersforimmunotherapyofnonsmallcelllungcancer
_version_	1718420335012872192

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer

Ejemplares similares